Similarly to aggressive B-cell lymphomas, this group of tumors has a complex genomic landscape with numerous copy number anomalies, and rearrangements of MYC and BCL2 are detected in 11–21% and 9–29% of cases, respectively [9]. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.